We are live on
!
Find out more
EARNEST Partners Portfolio holdings
AUM
$27.7B
1-Year Est. Return
52.44%
This Fund
S&P 500
This Quarter
Est. Return
+7.57%
1 Year Est. Return
+52.44%
3 Year Est. Return
+92.17%
5 Year Est. Return
+120.28%
10 Year Est. Return
+519.8%
AUM
$10B
AUM Growth
+$518M
(+5.4%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-1.05%
Top 10 Holdings %
Top 10 Hldgs %
18.87%
Holding
233
New
8
Increased
78
Reduced
133
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Darling Ingredients
DAR
|
+$67.4M |
| 2 |
EastGroup Properties
EGP
|
+$40.3M |
| 3 |
PENN Entertainment
PENN
|
+$33.5M |
| 4 |
Arrow Electronics
ARW
|
+$32M |
| 5 |
Avnet
AVT
|
+$17.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$99.4M |
| 2 |
TSMC
TSM
|
+$29.1M |
| 3 |
FPO
First Potomac Realty Trust
FPO
|
+$24.9M |
| 4 |
Icon
ICLR
|
+$16.9M |
| 5 |
VWR
VWR Corporation
VWR
|
+$15.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.16% |
| 2 | Industrials | 19.65% |
| 3 | Technology | 15.19% |
| 4 | Healthcare | 13.48% |
| 5 | Consumer Discretionary | 9.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Icon
ICLR
$13.1B
| $299M | 2.98% |
2,627,524
-158,584
| -6% | -$16.9M |
|
2
Core Laboratories
CLB
$567M
| $193M | 1.92% |
1,951,719
+115,982
| +6% | +$11.2M |
|
3
Carnival Corporation Ltd
CCL
$33.9B
| $192M | 1.92% |
2,978,036
-74,144
| -2% | -$4.96M |
|
4
Global Payments
GPN
$24.3B
| $187M | 1.87% |
1,971,879
-72,865
| -4% | -$6.87M |
|
5
Raymond James Financial
RJF
$34.5B
| $180M | 1.79% |
3,198,531
-27,117
| -0.8% | -$1.46M |
|
6
HDFC Bank
HDB
$119B
| $178M | 1.78% |
7,403,240
+101,024
| +1% | +$2.4M |
|
7
Novartis
NVS
$292B
| $172M | 1.72% |
2,238,994
-48,871
| -2% | -$3.69M |
|
8
Banco Bradesco
BBD
$34.4B
| $168M | 1.67% |
26,648,247
-682,416
| -2% | -$3.96M |
|
9
Entegris
ENTG
$20.6B
| $162M | 1.62% |
5,625,348
-28,532
| -0.5% | -$726K |
|
10
ICICI Bank
IBN
$107B
| $162M | 1.62% |
18,959,185
-1,461,187
| -7% | -$13.4M |
|
11
Hexcel
HXL
$7.17B
| $161M | 1.61% |
2,806,392
+18,602
| +0.7% | +$1M |
|
12
Centene
CNC
$32B
| $157M | 1.56% |
3,238,334
-135,064
| -4% | -$5.81M |
|
13
Snap-on
SNA
$20.3B
| $152M | 1.51% |
1,020,498
-5,596
| -0.5% | -$841K |
|
|
COHR
14
DELISTED
Coherent Inc
COHR
| $150M | 1.49% |
636,910
+6,066
| +1% | +$1.46M |
|
15
Reinsurance Group of America
RGA
$16B
| $148M | 1.47% |
1,057,466
-2,177
| -0.2% | -$294K |
|
16
Advanced Energy
AEIS
$10.9B
| $144M | 1.43% |
1,782,618
-56,461
| -3% | -$4.09M |
|
17
Everest Group
EG
$14.5B
| $141M | 1.4% |
616,326
-36,615
| -6% | -$9.23M |
|
18
Grupo Cibest SA
CIB
$23B
| $135M | 1.35% |
2,956,142
+111,384
| +4% | +$5.02M |
|
19
ScottsMiracle-Gro
SMG
$3.52B
| $128M | 1.28% |
1,316,284
+10,341
| +0.8% | +$980K |
|
|
CS
20
DELISTED
Credit Suisse Group
CS
| $120M | 1.19% |
7,588,346
+451,238
| +6% | +$6.85M |
|
21
Equinor
EQNR
$98.2B
| $119M | 1.19% |
5,926,826
+415,914
| +8% | +$7.68M |
|
22
Littelfuse
LFUS
$10.3B
| $115M | 1.14% |
584,901
-2,056
| -0.4% | -$373K |
|
23
Magna International
MGA
$17.6B
| $112M | 1.12% |
2,104,069
-39,129
| -2% | -$1.9M |
|
24
Rio Tinto
RIO
$168B
| $108M | 1.08% |
2,290,619
-52,180
| -2% | -$2.43M |
|
|
WGL
25
DELISTED
Wgl Holdings
WGL
| $107M | 1.06% |
1,269,627
+19,615
| +2% | +$1.66M |
|
Similar funds
CAM
UIM
SSA
CM
EARNEST Partners's Q3 2017 Portfolio in Review
As of Q3 2017, EARNEST Partners held 233 positions worth $10B, up 5.4% from $9.52B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
EARNEST Partners's Q3 2017 filing shows 8 new, 78 increased, 133 reduced and 4 closed positions. Its largest new stake was Darling Ingredients: 3,984,504 shares worth $69.8M. The largest sale was Teva Pharmaceuticals, an estimated $99.4M.
By sector, the portfolio is most concentrated in Financials at 23% of assets, down from 23% a quarter earlier, followed by Industrials and Technology.
- EARNEST Partners's largest Q3 2017 buy was Darling Ingredients: 3,984,504 shares worth $69.8M.
- EARNEST Partners added most to Core Laboratories in Q3 2017, an estimated $11.2M increase.
- EARNEST Partners's biggest Q3 2017 reduction was TSMC, cutting an estimated $29.1M.
- EARNEST Partners fully exited Teva Pharmaceuticals in Q3 2017, selling an estimated $99.4M.
- EARNEST Partners's ten largest holdings make up 19% of its $10B portfolio in Q3 2017.
- EARNEST Partners opened 8 new positions and closed 4 in Q3 2017.
- EARNEST Partners's portfolio value rose 5.4% quarter-over-quarter to $10B.
Based on EARNEST Partners's 13F filing for Q3 2017, filed 14 Nov 2017.